Clinical Trials Logo

Gram-negative Bacteremia clinical trials

View clinical trials related to Gram-negative Bacteremia.

Filter by:

NCT ID: NCT06214403 Not yet recruiting - Clinical trials for Microbial Colonization

Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation

ARO-DECAMP
Start date: July 2024
Phase: Phase 2
Study type: Interventional

ARO-DECAMP is a multi-centre, placebo-controlled, pilot and feasibility randomized controlled trial for the microbial consortium Microbial Ecosystem Therapeutic-2. Non-intensive care unit patients ≥ 18 years old diagnosed with a bloodstream infection and receiving treatment for an antibiotic resistant organism will be included. Participants will be randomized to receive either MET-2 or placebo for 10 days. Recruitment rate and study intervention adherence will be evaluated for feasibility. Participants will be followed for 180 days, and biological samples will be collected periodically for clinical, ecological, and biomarker outcomes.

NCT ID: NCT06174649 Recruiting - Clinical trials for Bloodstream Infection

Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial

FAST
Start date: December 22, 2023
Phase: N/A
Study type: Interventional

This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive blood cultures characterized using standard of care (SOC) antimicrobial susceptibility testing (AST) vs. a rapid AST method known as Reveal™ in addition to SOC AST. The purpose of the FAST trial is to evaluate whether use of a rapid phenotypic AST improves clinical outcomes compared to use of SOC AST methods in clinical settings with high resistance rates.

NCT ID: NCT06080698 Recruiting - Clinical trials for Gram-negative Bacteremia

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

GOAT
Start date: February 22, 2024
Phase: N/A
Study type: Interventional

The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.

NCT ID: NCT05893147 Recruiting - Clinical trials for Gram-negative Bacteremia

BALANCE+ Vanguard Phase

BALANCE+
Start date: August 26, 2023
Phase: N/A
Study type: Interventional

The goal of the BALANCE+ clinical trial is to transform random care to randomized care for patients with Gram negative bloodstream infections to inform best treatment approaches and optimize outcomes. BALANCE+, a perpetual platform trial, will efficiently answer multiple questions that are important for hospitalized patients with Gram negative bloodstream infections.

NCT ID: NCT05605275 Completed - Sepsis Clinical Trials

CRP and PCT as Predictors of Sepsis Cause

Start date: January 5, 2022
Phase:
Study type: Observational

The aim of this retrospective study is to determine the predictive role of serum level of procalcitonin (PCT) and c-reactive protein (CRP) in determining the causative agent of sepsis in surgical intensive care unit (ICU) patients. The main question it aims to answer is: what serum level of PCT and CRP is predictive of gram+ and gram- sepsis in patients with positive blood cultures in the surgical ICU. The study will be retrospective and will include all patients with positive blood cultures who were hospitalized in the surgical ICU of University Hospital Osijek in the period from January 2019 to May 2022.

NCT ID: NCT04291768 Recruiting - Clinical trials for Gram-negative Bacteremia

Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia

GNB5
Start date: March 11, 2020
Phase: Phase 4
Study type: Interventional

GNB5 is an investigator-initiated multicentre non-inferiority randomized controlled trial which aims to assess the efficacy and safety of shortened antibiotic for patients hospitalized with a Gram negative bacteremia with a urinary tract source of infection (GNB). Five days after initiation of antimicrobial therapy for GNB, participants are randomized 1:1 to parallel treatment arms: 5 days (intervention) or minimum 7 days (control) of antibiotic treatment. The intervention group discontinues antibiotics at day 5 if clinically stable and afebrile. The control group receives antibiotics for a duration of 7 days or longer at the discretion of the treating physician. The primary outcome is 90-day survival without clinical or microbiological failure to treatment, which will be tested with a non inferiority margin of 10%.

NCT ID: NCT04055922 Enrolling by invitation - Clinical trials for Gram-Negative Bacterial Infections

Comparison of Solid Organ Transplant

Start date: May 3, 2018
Phase:
Study type: Observational

Solid organ transplant (SOT) recipients have increased incidence of infections with MDRO pathogens. This difference leads to a disparity in antibiograms between SOT recipients and other hospitalized patients.

NCT ID: NCT03745014 Withdrawn - Clinical trials for Gram-negative Bacteremia

Clinical Impact of Fast Phenotypic Antimicrobial Susceptibility Testing on Patients With Gram-Negative Rod Bacteremia

Start date: September 30, 2019
Phase: N/A
Study type: Interventional

The FDA-cleared Accelerate Pheno™ System and PhenoTest™ Blood Culture (BC) Kit will be used to assess the workflow impact of fast identification (ID)/ antimicrobial susceptibility testing (AST) in the microbiology lab and in the quality of care in patients with Gram-negative rod (GNR) bacteremia. Blood culture work up will be randomized to one of two arms: the positive blood culture will either undergo fast ID and AST using the Accelerate Pheno™ System and PhenoTest™ BC Kit or processing per the site's standard of care (SOC) procedures.

NCT ID: NCT03218397 Completed - Clinical trials for Gram-negative Bacteremia

Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia

RAPIDS-GN
Start date: October 9, 2017
Phase: N/A
Study type: Interventional

RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1. Standard culture and antimicrobial susceptibility testing (AST); or 2. Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)

NCT ID: NCT02599220 Completed - Bacteremia Clinical Trials

Clinical Outcomes and Cost of Gram Negative Bacteremia

Start date: January 2002
Phase: N/A
Study type: Observational

This study examines the clinical outcomes and healthcare costs associated with gram negative bacteremia at Duke University Medical Center from 2002-2015.